Mientras MISSD se prepara para participar el próximo mes en el Foro Regional Panamericano de la Asociación Internacional para la Prevención del Suicidio (IASP) en Costa Rica, seguimos ampliando nuestros esfuerzos para llegar a más comunidades de habla hispana.

Hemos añadido tres videos de salud pública en español a nuestro canal de YouTube, ofreciendo a más personas acceso gratuito a información sobre la acatisia, un trastorno inducido por medicamentos que puede poner en peligro la vida y que con frecuencia pasa desapercibido o se diagnostica erróneamente.

Los videos explican qué es la acatisia, cómo reconocer sus síntomas y por qué la concienciación y la identificación temprana son fundamentales para la seguridad del paciente.

Ofrecer estos recursos en español es un paso más para ayudar a pacientes, familiares, cuidadores y profesionales de la salud a reconocer la acatisia y prevenir daños evitables.

Mira y comparte nuestros nuevos videos en español: https://www.youtube.com/playlist?list=PLAlH6bAdfTt4.

As MISSD prepares to present at next month’s International Association for Suicide Prevention (IASP) Pan-American Regional Forum in Costa Rica, we’re expanding our efforts to reach more Spanish-speaking communities.

We’ve added three Spanish-language public health videos to our YouTube channel, providing more people with free, accessible information about akathisia, a serious medication-induced disorder that is frequently overlooked or misdiagnosed.

The videos explain what akathisia is, how to recognize its symptoms, and why awareness and early identification are essential to patient safety.

Making these resources available in Spanish is another step toward helping patients, families, caregivers, and healthcare professionals recognize akathisia and prevent avoidable harm.

Watch and share the on MISSD’s YouTube channel at: https://www.youtube.com/playlist?list=PLAlH6bAdfTt4.

Akathisia isn’t as rare as drug companies lead patients and doctors to believe —and it can occur after stopping a medication.

In this podcast clip from Akathisia Stories, Kristina discusses how stopping or sharply reducing a drug associated with akathisia can also trigger the disorder.

Visit MISSD’s YouTube channel for more video shorts, podcasts, and public health videos to learn more about akathisia. Awareness and accurate info can help save a life.

Patients and families deserve clear, accessible information about medication risks. Today the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has announced new measures to strengthen communication about antidepressant risks. They include the risks of suicidal thoughts and behaviors and sexual dysfunction that may persist even after treatment ends.

The measures include a boxed warning in patient information leaflets, a new patient safety card, and updated wording about persistent sexual side effects for certain antidepressants. An additional safety leaflet explaining benefits, risks, and alternatives is planned for 2027.

These measures address existing risks—not newly discovered ones. For MISSD, they underscore why fully informed consent and listening to patients’ experiences matter.

Read the MHRA announcement at: https://www.gov.uk/drug-safety-update/antidepressants-new-safety-measures-for-all-patients-to-improve-communication-of-the-risk-of-suicidal-thoughts-and-behaviours-and-persistent-sexual-dysfunction.

Your generosity helped MISSD bring akathisia education and awareness to more people in more places. Explore our 2026 highlights and see how you can help continue this vital work in 2027.

A recent Psychiatric Times review examines medications used to reduce suicide risk. It also calls for closer monitoring around medication changes. But it does not discuss akathisia or medication-induced suicidality.

That omission matters. Akathisia is a medication-induced neuropsychiatric disorder that is often mistaken for anxiety or another DSM-labeled disorder.

MISSD’s message is not that medications never help. It is that a sudden crisis calls for a careful look at what changed—including medications. If someone develops severe restlessness, agitation, or suicidal thoughts after starting, stopping, or changing a medication or dose, akathisia must be considered and should be assessed.

Prescribers and consumers need to ask the question that could change the response: Could this be akathisia?